1-8 of 8
Yanli Yang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-world survival of IDH-mutant patients in China before IDH-inhibitor era: A multicenter retrospective study from anhui cooperative hematology group(ACHG)

Free
Enbo Chen, Xuemei Wu, Yuanfeng Wei, Zihan Chen, Junjie Zhou, Yanli Yang, Jian Ge
Journal: Blood
Blood (2025) 146 (Supplement 1): 3389.
https://doi.org/10.1182/blood-2025-3389
Published: 2025
Journal Articles

Practice pattern and outcomes in DLBCL by Genetic Subtypes: Preliminary results from a large-scale real-world study in China

Free
Pengpeng Xu, Hongmei Jing, Songfu Jiang, Keshu Zhou, Wenrong Huang, Xiaoxi Zhou, Jianzhen Shen, Xiuhua Sun, Xiaobo Wang, Bing Xiu, Xiaojing Yan, Ting Niu, Hongling Peng, Haisheng Liu, Sujiang Zhang, Wei Sang, Yanli Yang, Yingyu Nan, Yao Liu, Wuping Li, Lijie Xing, Chunling Wang, Jingyan Xu, Qianqian Cai, Ying Zhao, Xudong Zhang, Zhengzi Qian, Jinhai Ren, Aili He, Li Wang, Yue Wang, Muchen Zhang, Yang He, Wei Li Zhao
Journal: Blood
Blood (2025) 146 (Supplement 1): 3689.
https://doi.org/10.1182/blood-2025-3689
Published: 2025
Journal Articles

Mesutoclax (ICP-248) monotherapy or combined with orelabrutinib demonstrates encouraging activity and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Free
Yang Liang, Shuhua Yi, Keshu Zhou, Jie Jin, Wenjuan Yu, Jian Ge, Zunmin Zhu, Aijun Liao, Hongling Peng, Fang Zhou, Xiaobing Huang, Guohui Cui, Fei Li, Hongmei Jing, Mingxia Shi, Xiaoqiong Tang, Li Wang, Zhiming Li, Shihua Huang, Liqun Zou, Zengjun Li, Jian-Qing Mi, Yanli Yang, Wei Yang, Jing Cao, Weige Wang, Chen Luo, Renbin Zhao, Lugui Qiu, Wei Xu
Journal: Blood
Blood (2025) 146 (Supplement 1): 5677.
https://doi.org/10.1182/blood-2025-5677
Published: 2025
Journal Articles

Efficacy and safety of mitoxantrone hydrochloride liposome in peripheral T-cell lymphoma: A multicenter, non-interventional, ambispective cohort real-world study

Free
Donglu Zhao, Huiqiang Huang, Zhiming Li, Lihong Liu, Quande Lin, Jun Fang, Kaiyang Ding, Jie Jin, Yanhong Tong, Dengju Li, Zengjun Li, Liping Su, Liang Wang, Wenbin Qian, Xiuhua Sun, Xiaobo Wang, Pengcheng He, Wei Yang, Jinhai Ren, Liling Zhang, Zunmin Zhu, Lugui Qiu, Dehui Zou, Wei LIU, Hui Zhou, Dongfeng Luo, Xiaojing Yan, Zhenqian Huang, Lintao Bi, Rong FU, Yunhong Huang, Aichun Liu, Xi Zhang, Yao Liu, Hao Zhang, Guangxun Gao, Liangquan Geng, Jingbo Wang, Jia Li, Yi Wang, Liqun Zou, Ming Jiang, Jian Ge, Xiu Li Sun, Yanli Yang, Hongmei Jing, Kai Hu, Zhimin Yan, Shuangnian Xu, Xiangxiang Zhou, Ganggang Wang, Zhilin Gao, Li Liang, Hongfeng Ge, Qingshan Li, Zhixue Zhang, Wuping Li, Xiaojing Xing, Fengzi Wang, Dongping Huang, Jun Qian, Hua Fan, Chanjuan Shen, Jun Ma
Journal: Blood
Blood (2025) 146 (Supplement 1): 1878.
https://doi.org/10.1182/blood-2025-1878
Published: 2025
Journal Articles

Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Free
Wenming Chen, Chengcheng Fu, Baijun Fang, Aibin Liang, Zhongjun Xia, Yanjuan He, Jin Lu, Hui Liu, Ming Hou, Zhen Cai, Wei Yang, Siguo Hao, Songfu Jiang, Hongmei Jing, Jing Liu, Xin Du, Rong Fu, Heng Mei, Zunmin Zhu, Yanli Yang, Hong Liu, Xingxing Meng, Nishanthan Rajakumaraswamy, Wei Zheng, Huamao Wang, Zonghai Li
Journal: Blood
Blood (2024) 144 (Supplement 1): 4762.
https://doi.org/10.1182/blood-2024-204620
Published: 2024
Journal Articles

Phase Ⅱ Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Free
Wenming Chen, Chengcheng Fu, Baijun Fang, Aibin Liang, Zhongjun Xia, Yanjuan He, Jin Lu, Hui Liu, Ming Hou, Zhen Cai, Wei Yang, Siguo Hao, Songfu Jiang, Hongmei Jing, Jing Liu, Xin Du, Rong Fu, Heng Mei, Zunmin Zhu, Yanli Yang, Hong Liu, Daijing Yuan, Hongxia Zhao, Jun Xiao, Wei Wang, Huamao Wang, Zonghai LI
Journal: Blood
Blood (2022) 140 (Supplement 1): 4564–4565.
https://doi.org/10.1182/blood-2022-168610
Published: 2022
Journal Articles

The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Orelabrutinib in Chinese Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Updated Results of a Multicenter, Phase I/IIa Trial

Free
Yuankai Shi, Yan Qin, Aimin Zang, Yufu Li, Yanli Yang, Hui Liu, Sujun Gao, Xinghe Wang, Weijing Zhang, Zhengming Jin, Hui Zhou, Wang Hua-Qing, Min Wei
Journal: Blood
Blood (2022) 140 (Supplement 1): 9482–9483.
https://doi.org/10.1182/blood-2022-162984
Published: 2022
Journal Articles

First in Human (FIH) Study of GFH009, a Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, in Patients with Relapsed/Refractory (r/r) Hematologic Malignancies

Free
Junyuan Qi, Keshu Zhou, Wenbin Qian, Aimin Zang, Tapan M. Kadia, Andrew H. Lipsky, Yanli Yang, Yu Wang, Haige Shen, Bo Zheng, Chanli Zheng, Dragan Cicic, Jianxiang Wang
Journal: Blood
Blood (2022) 140 (Supplement 1): 9473–9474.
https://doi.org/10.1182/blood-2022-159844
Published: 2022